Veozah, illustration of tablet form (not a photo of the actual pack)

Illustrative image.

Veozah

Fezolinetant

Prescription required

$450.00

45mg · 3 × 30 tablets · 3 months supply

BrandBranded medicine· By Astellas

$150.00 per month

How long a supply?

1 month$150.00 a month
3 months$150.00 a month
6 months$150.00 a month
Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$1800a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningRisks of hepatotoxicity

Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting.

Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2 x the upper limit of normal (ULN) or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.

Perform follow-up hepatic laboratory testing monthly for the first 3 months, at 6 months, and 9 months of treatment.

Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain).

Discontinue VEOZAH if transaminase elevations are > 5 x ULN, or if transaminase elevations are > 3 x ULN and the total bilirubin level is > 2 x ULN.

If transaminase elevations > 3 x ULN occur, perform more frequent follow-up hepatic laboratory tests until resolution.

Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.

Read this with the rest of the clinical information

About Veozah

Overview

Veozah is a prescription medicine containing fezolinetant. It is used to treat moderate to severe vasomotor symptoms due to menopause, such as hot flashes. It works by blocking neurokinin 3 (NK3) receptors to help regulate nerve activity in the brain’s temperature-control centre.

What it treats

Moderate to severe vasomotor symptoms due to menopause.

Safety information

Side effects

Common side effects of Veozah include abdominal pain, diarrhea, difficulty sleeping, back pain, hot flushes and raised liver enzyme levels. Liver injury and jaundice have been reported. Stop taking Veozah immediately and seek medical attention if you develop new tiredness, decreased appetite, nausea, vomiting, itching, yellowing of the skin or eyes, pale stools, dark urine or abdominal pain. You will need liver blood tests to check for possible liver injury. Liver blood tests are required before starting treatment, monthly for the first 3 months, and at 6 and 9 months after starting treatment.

FDA boxed warning

Risks of hepatotoxicity

Hepatotoxicity has occurred with the use of VEOZAH in the postmarketing setting.

Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2 x the upper limit of normal (ULN) or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.

Perform follow-up hepatic laboratory testing monthly for the first 3 months, at 6 months, and 9 months of treatment.

Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain).

Discontinue VEOZAH if transaminase elevations are > 5 x ULN, or if transaminase elevations are > 3 x ULN and the total bilirubin level is > 2 x ULN.

If transaminase elevations > 3 x ULN occur, perform more frequent follow-up hepatic laboratory tests until resolution.

Perform hepatic laboratory tests prior to initiation of treatment to evaluate for hepatic function and injury. Do not start VEOZAH if either aminotransferase is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Stop taking Veozah immediately and seek medical attention, including liver blood tests, if you develop any of these possible signs of liver injury: - New tiredness, loss of appetite, nausea or vomiting. - Itching or yellowing of the skin or eyes. - Pale stools or dark urine. - Abdominal pain.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Veozah (fezolinetant) if you have known cirrhosis, severe kidney impairment or end-stage kidney disease, or if you take medicines that inhibit the enzyme CYP1A2. Liver injury and jaundice have been reported with Veozah. Liver blood tests are required before starting treatment, monthly for the first 3 months, and at 6 and 9 months after starting. Stop taking Veozah immediately and seek medical attention, including liver blood tests, if you develop new fatigue, decreased appetite, nausea, vomiting, itching, yellowing of the skin or eyes, pale stools, dark urine or abdominal pain.

Interactions

Veozah must not be taken with medicines that inhibit the liver enzyme CYP1A2, as these can increase fezolinetant levels in the blood and the risk of side effects. Examples include fluvoxamine, ciprofloxacin and cimetidine. This is not a complete list. Tell your doctor or pharmacist about all prescription and non-prescription medicines, vitamins and herbal supplements you take. Check before starting any new medicine or supplement while taking Veozah.

Using Veozah

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label VEOZAH (FEZOLINETANT) TABLET, FILM COATED [ASTELLAS PHARMA US, INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines